Medical research indicates CBD shows potential for decreasing seizure frequency among patients with treatment-resistant epilepsy though stronger evidence remains to be obtained.

Medical studies that reviewed CBD benefits through systematic methods and combined statistical data demonstrate its ability to lower seizure counts in pharmacoresistant epilepsy patients. Future investigations must proceed because the current data shows promising results.

The worldwide presence of epilepsy reaches 50 million people while drug-resistant epilepsy conditions stand at 20% of all cases. People with this condition do not achieve proper seizure control when using standard antiepileptic drugs. The non-intoxicating cannabinoid CBD has established itself as a therapeutic compound that some nations now accept for medical use. Australia has authorized a special CBD formula to address seizures within patients who suffer from Lennox-Gastaut and Dravet syndromes.

Scientists from Tiradentes University together with Universidade de São Paulo conducted a review of six studies about CBD effectiveness. Patients got better results with CBD treatments because they achieved a 41.1% seizure reduction rate beyond the 18.1% decrease seen in placebo recipients. The treatment outcomes using CBD exceeded those of placebo by 127% according to research findings.

The positive outcomes of CBD treatment came with adverse effects that caused patients to experience sleepiness at rates ranging from 24.5% to 28.2% as well as a decreased appetite between 20.1% to 25.7% and diarrhea appearing in 18.2% to 21.9% of cases. Research data indicates CBD should appear as a therapeutic option for future epilepsy treatment standards in both healthcare facilities and nationwide health programs. The researchers propose additional research that uses alternative analytical methods to verify CBD efficacy due to high placebo response levels.